Nghiên cứu sự thay đổi AFP, AFP-L3, PIVKA-II trước và sau điều trị bệnh nhân ung thư biểu mô tế bào gan

The purpose of this study is to evaluate the role of three markers AFP, AFP-L3, PIVKA-II in evaluating the treatment of patients with hepatocellular carcinoma. Subjects and methods: A total 29 patients with hepatocellular carcinoma participating in the study evaluated the clinical, laboratory and response characteristics of AFP, AFP-L3, PIVKA-II after 1 month of treatment and 3 months. Results: In 29 patients, the mean age of patients was 60.5 ±10.1 years. The risk factors for liver cancer are hepatitis B and C viruses and alcohol. The combination of three markers AFP, AFP-L3 and PIVKA-II increases the sensitivity in the diagnosis of HCC compared with the use of each marker alone. After 1 month and 3 months of treatment with TACE or RFA in HCC patients, mean serum levels of AFP, AFP-L3 and PIVKA-II markers decreased compared with before treatment. Conclusions: The combination of three markers AFP, AFP-L3 and PIVKA-II increases the predictive power of imaging response after treatment of HCC patients compared with the use of each marker alone.